News & Updates

Show Multimedia Only

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

06 Nov 2025 by

First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

06 Nov 2025

Anti-synthetase syndrome linked to cancer-related myositis

06 Nov 2025

Patients with anti-synthetase syndrome show a higher incidence of cancer-related myositis than the general population, suggests a study.

Anti-synthetase syndrome linked to cancer-related myositis

06 Nov 2025

FIT kit-dispensing kiosk to promote uptake of CRC screening in SG

05 Nov 2025 by

An automated kiosk that dispenses faecal immunochemical test (FIT) kits, called the KIPFIT*, has the potential to increase colorectal (CRC) screening uptake in Singapore, as shown in a study.

FIT kit-dispensing kiosk to promote uptake of CRC screening in SG

05 Nov 2025

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

05 Nov 2025 by

An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

05 Nov 2025

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025 by

Treatment with tislelizumab results in longer overall survival (OS), prolonged progression-free survival (PFS), higher objective response rates (ORRs), more durable responses, and fewer grade ≥3 treatment-emergent (TEAEs) and treatment-related adverse events (TRAEs) compared with docetaxel, according to the RATIONALE-303 study.

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

05 Nov 2025

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

05 Nov 2025 by

The world’s first randomized controlled trial (RCT) of lipofilling for immediate breast reconstruction in breast-conserving surgery (BCS), conducted by researchers from the University of Hong Kong (HKU), has shown promising preliminary results and continues to recruit patients.

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

05 Nov 2025

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025 by

Neoadjuvant treatment with tiragolumab plus atezolizumab, with or without chemotherapy, is feasible in advanced resectable non-small cell lung cancer (NSCLC), having an acceptable safety profile and yielding major pathologic response (MPR) rates comparable to that observed with other perioperative immunotherapy plus chemotherapy regimens, according to the phase II SKYSCRAPER-05 trial.

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

04 Nov 2025

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

04 Nov 2025

Some patients with nonsmall-cell lung cancer (NSCLC) have somatic DNA methyltransferase 3A (DNMT3A) mutations, which are associated with a reduced DNMT3A expression and a favourable immunophenotype, reveals a study.

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

04 Nov 2025

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

03 Nov 2025 by

In the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), the combination of cemiplimab plus chemotherapy continued to provide superior benefits compared with chemotherapy alone, according to 5-year data from the phase III EMPOWER-Lung part 2 trial.

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

03 Nov 2025

Extended PLND tied to improved survival in bladder cancer

03 Nov 2025

In patients with bladder cancer, extended pelvic lymph node dissection (PLND) is associated with favourable recurrence-free survival and 5-year recurrence rates, a study has shown.

Extended PLND tied to improved survival in bladder cancer

03 Nov 2025

News & Updates

Showing Oncology articles

Showing

Specialty:

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

Anti-synthetase syndrome linked to cancer-related myositis

Anti-synthetase syndrome linked to cancer-related myositis

FIT kit-dispensing kiosk to promote uptake of CRC screening in SG

FIT kit-dispensing kiosk to promote uptake of CRC screening in SG

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

Tislelizumab outclasses docetaxel in advanced/metastatic NSCLC

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

World’s first RCT on lipofilling in breast-conserving surgery shows promising preliminary results

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

Pre-op tiragolumab plus atezolizumab viable in advanced NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

DNMT3A mutations predict PD-(L)1 blockade efficacy in NSCLC

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

Patients with advanced NSCLC get durable benefits with frontline cemiplimab plus chemo

Extended PLND tied to improved survival in bladder cancer

Extended PLND tied to improved survival in bladder cancer